The device is FDA cleared and uses a medical-grade foam ball compressed into a swallowable capsule, allowing for non-endoscopic specimen collection and diagnosis of patients. The company plans to launch a new FDA 510k cleared non-endoscopic screening device for esophageal cellular retrieval, which will be used in conjunction with new genome sequencing diagnostic tests. These tests are expected to become mass "out-patient" screening tests for early detection of Barrett's Esophagus and other diseases. This provides an opportunity for the company to expand its product line and increase its impact in the medical field.